Candel Therapeutics Analyst Ratings
BenzingaNov 13, 2023 08:46 ET
Candel Therapeutics' Promising Clinical Progress and Financial Stability: A Buy Recommendation
TipRanksNov 13, 2023 06:37 ET
Promising Potential of CAN-2409 Elevates Candel Therapeutics to a Buy Rating: A Detailed Analysis
TipRanksSep 26, 2023 10:15 ET
H.C. Wainwright Sticks to Their Buy Rating for Candel Therapeutics (CADL)
TipRanksAug 24, 2023 10:35 ET
Candel Therapeutics (CADL) Receives a Buy From H.C. Wainwright
TipRanksMay 22, 2023 06:25 ET
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
BenzingaMay 22, 2023 06:16 ET
BMO Capital Maintains Outperform on Candel Therapeutics, Lowers Price Target to $3
BenzingaMay 15, 2023 08:31 ET
Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $7
BenzingaMar 31, 2023 08:57 ET
Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating
MT NewswiresMar 31, 2023 08:48 ET
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating
MT NewswiresDec 9, 2022 10:03 ET
H.C. Wainwright Keeps Their Buy Rating on Candel Therapeutics (CADL)
TipRanksDec 8, 2022 08:35 ET
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating
MT NewswiresDec 8, 2022 05:57 ET
BMO Capital Reaffirms Their Buy Rating on Candel Therapeutics (CADL)
TipRanksDec 7, 2022 10:10 ET
Candel Therapeutics Analyst Ratings
Benzinga Analyst RatingsDec 7, 2022 07:57 ET
Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $8
Benzinga Real-time NewsDec 7, 2022 07:57 ET
Candel Therapeutics Analyst Ratings
Benzinga Analyst RatingsDec 2, 2022 06:32 ET
HC Wainwright & Co. Initiates Coverage On Candel Therapeutics With Buy Rating, Announces Price Target of $11
Benzinga Real-time NewsDec 2, 2022 06:32 ET
No Data
No Data